The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Roche’s Flatiron Health and the U.S. Food and Drug Administration’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement.
Voyager Therapeutics struck a deal with AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.
Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.
Shares of Immune Design skyrocketed after Merck announced the acquisition of the Seattle-based oncology company for $300 million in cash.
German drugmaker Bayer acquired all rights the company does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly’s Loxo Oncology.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Argenx and Halozyme Therapeutics signed a global collaboration and license deal that allows Argenx to use Halozyme’s Enhanze drug delivery technology to develop multiple products.
Two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.
Gilead Sciences Inc. is acquiring the global rights to develop and commercialize novel small molecules against two targets from South Korea-based Yuhan Corporation.
Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!
